A bold move by President Donald Trump has the potential to revolutionize access to weight loss medications, but it's not without its controversies. Get ready to dive into the details of these landmark deals!
The Cost of Weight Loss: A New Era?
Trump has struck agreements with pharmaceutical giants Eli Lilly and Novo Nordisk to drastically reduce the prices of their popular weight loss drugs. Under these deals, patients could expect to pay anywhere from $50 to $350 per month for injections and upcoming pills, a significant drop from the current list prices of over $1,000.
But here's where it gets controversial: these deals are part of Trump's "most favored nation" policy, which aims to expand access to these medications even further. Let's explore how these agreements could impact patients.
Medicare: A New Benefit for Seniors
Medicare, a federal health insurance program, has traditionally covered GLP-1 drugs for diabetes and certain other conditions. However, under the new deals, Medicare will now cover these drugs for obesity treatment, starting in mid-2026. This could be a game-changer for seniors, as it may allow more of them to qualify for these medications and encourage private insurers to follow suit.
Certain Medicare patients will pay a copay of $50 per month for all approved uses of GLP-1 drugs, including diabetes and obesity treatment. But the Trump administration has set some eligibility criteria for Medicare beneficiaries to receive GLP-1s for obesity and cardiovascular benefits.
Patients must fall into one of these three cohorts to be eligible:
- Overweight individuals with a BMI greater than 27, or those with prediabetes or established cardiovascular disease.
- People with obesity (BMI > 30) and uncontrolled hypertension, kidney disease, or heart failure.
- Patients with severe obesity, defined as a BMI greater than 35.
A Voluntary Price Reduction
Eli Lilly and Novo Nordisk have voluntarily agreed to reduce the prices the government pays for existing GLP-1 drugs approved for diabetes and other uses to $245 per month for all non-starting doses. This move will generate savings that will allow Medicare to offer the same price point for GLP-1s to patients with obesity and high metabolic or cardiovascular risk.
Direct-to-Consumer: Steeper Discounts
The agreement also opens up the possibility for patients to access GLP-1s through direct-to-consumer platforms at even steeper discounts than those currently offered by drugmakers' websites.
On TrumpRx, the government's upcoming direct-to-consumer platform for purchasing prescription drugs with cash, the average monthly cost for Wegovy, Zepbound, and other injectable GLP-1s will start at $350 and drop to $250 within two years. Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $145 per month on TrumpRx, Medicare, and Medicaid.
Eli Lilly has announced that it will lower prices by $50 on its own direct-to-consumer platform, LillyDirect, which already offers Zepbound and other drugs at a discount to cash-paying patients. The lowest dose of the multidose pen of Zepbound will be available for $299 per month, with additional doses priced up to $449 per month.
Once approved, Eli Lilly's pill will start at $149 per month for the lowest dose.
Medicaid: Spotty Coverage, But a Step Forward
State Medicaid coverage of GLP-1 drugs for obesity is inconsistent. However, Novo Nordisk and Eli Lilly have agreed to extend lower government pricing for their GLP-1 drugs - $245 per month for all non-starting doses - to all 50 Medicaid programs for all covered uses. This is a significant step forward, but states will have the option to opt-in, so coverage may vary.
And this is the part most people miss: these deals are just the beginning. With the potential for more affordable weight loss medications, the question arises: how will this impact the obesity epidemic and the overall health of the nation?
What are your thoughts on these agreements? Do you think they will make a significant difference in the fight against obesity? We'd love to hear your opinions in the comments!
